Matthew J Nyflot1, Tim J Kruser2, Anne M Traynor3, Deepak Khuntia4, David T Yang5, Gregory K Hartig6, Timothy M McCulloch6, Peggy A Wiederholt7, Lindell R Gentry8, Tien Hoang3, Robert Jeraj9, Paul M Harari7. 1. Department of Radiation Oncology, University of Washington, Seattle, Washington. Electronic address: nyflot@uw.edu. 2. Department of Radiation Oncology, Cadence Cancer Center at Delnor Hospital, Geneva, Illinois. 3. Department of Medicine, University of Wisconsin Carbone Cancer Center and School of Medicine and Public Health, Madison, Wisconsin. 4. Varian Medical Systems, Palo Alto, California. 5. Departments of Pathology and Laboratory Medicine, University of Wisconsin Carbone Cancer Center and School of Medicine and Public Health, Madison, Wisconsin. 6. Department of Surgery-Otolaryngology, H&N Surgery Division, University of Wisconsin Carbone Cancer Center and School of Medicine and Public Health, Madison, Wisconsin. 7. Department of Human Oncology, University of Wisconsin Carbone Cancer Center and School of Medicine and Public Health, Madison, Wisconsin. 8. Department of Radiology, University of Wisconsin Carbone Cancer Center and School of Medicine and Public Health, Madison, Wisconsin. 9. Department of Human Oncology, University of Wisconsin Carbone Cancer Center and School of Medicine and Public Health, Madison, Wisconsin; Department of Radiology, University of Wisconsin Carbone Cancer Center and School of Medicine and Public Health, Madison, Wisconsin; Department of Medical Physics, University of Wisconsin Carbone Cancer Center and School of Medicine and Public Health, Madison, Wisconsin.
Abstract
PURPOSE: A phase 1 trial was completed to examine the safety and feasibility of combining bevacizumab with radiation and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) treated with curative intent. Additionally, we assessed the capacity of bevacizumab to induce an early tumor response as measured by a series of biological imaging studies. METHODS AND MATERIALS: All patients received a single induction dose of bevacizumab (15 mg/kg) delivered 3 weeks (±3 days) before the initiation of chemoradiation therapy. After the initial dose of bevacizumab, comprehensive head and neck chemoradiation therapy was delivered with curative intent to 70 Gy in 33 fractions with concurrent weekly cisplatin at 30 mg/m(2) and bevacizumab every 3 weeks (weeks 1, 4, 7) with dose escalation from 5 to 10 to 15 mg/kg. All patients underwent experimental imaging with [(18)F]fluorothymidine positron emission tomography (FLT-PET) (proliferation), [(61)Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) PET (Cu-ATSM-PET) (hypoxia), and dynamic contrast-enhanced computed tomography (DCE-CT) (perfusion) at 3 time points: before bevacizumab monotherapy, after bevacizumab monotherapy, and during the combined therapy course. RESULTS: Ten patients were enrolled. All had stage IV HNSCC, all achieved a complete response to treatment, and 9 of 10 remain alive, with a mean survival time of 61.3 months. All patients experienced grade 3 toxicity, but no dose-limiting toxicities or significant bleeding episodes were observed. Significant reductions were noted in tumor proliferation (FLT-PET), tumor hypoxia (Cu-ATSM-PET), and DCE-CT contrast enhancement after bevacizumab monotherapy, with further decreases in FLT-PET and Cu-ATSM-PET during the combined therapy course. CONCLUSIONS: The incorporation of bevacizumab into comprehensive chemoradiation therapy regimens for patients with HNSCC appears safe and feasible. Experimental imaging demonstrates measureable changes in tumor proliferation, hypoxia, and perfusion after bevacizumab monotherapy and during chemoradiation therapy. These findings suggest opportunities to preview the clinical outcomes for individual patients and thereby design personalized therapy approaches in future trials.
PURPOSE: A phase 1 trial was completed to examine the safety and feasibility of combining bevacizumab with radiation and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) treated with curative intent. Additionally, we assessed the capacity of bevacizumab to induce an early tumor response as measured by a series of biological imaging studies. METHODS AND MATERIALS: All patients received a single induction dose of bevacizumab (15 mg/kg) delivered 3 weeks (±3 days) before the initiation of chemoradiation therapy. After the initial dose of bevacizumab, comprehensive head and neck chemoradiation therapy was delivered with curative intent to 70 Gy in 33 fractions with concurrent weekly cisplatin at 30 mg/m(2) and bevacizumab every 3 weeks (weeks 1, 4, 7) with dose escalation from 5 to 10 to 15 mg/kg. All patients underwent experimental imaging with [(18)F]fluorothymidine positron emission tomography (FLT-PET) (proliferation), [(61)Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) PET (Cu-ATSM-PET) (hypoxia), and dynamic contrast-enhanced computed tomography (DCE-CT) (perfusion) at 3 time points: before bevacizumab monotherapy, after bevacizumab monotherapy, and during the combined therapy course. RESULTS: Ten patients were enrolled. All had stage IV HNSCC, all achieved a complete response to treatment, and 9 of 10 remain alive, with a mean survival time of 61.3 months. All patients experienced grade 3 toxicity, but no dose-limiting toxicities or significant bleeding episodes were observed. Significant reductions were noted in tumor proliferation (FLT-PET), tumor hypoxia (Cu-ATSM-PET), and DCE-CT contrast enhancement after bevacizumab monotherapy, with further decreases in FLT-PET and Cu-ATSM-PET during the combined therapy course. CONCLUSIONS: The incorporation of bevacizumab into comprehensive chemoradiation therapy regimens for patients with HNSCC appears safe and feasible. Experimental imaging demonstrates measureable changes in tumor proliferation, hypoxia, and perfusion after bevacizumab monotherapy and during chemoradiation therapy. These findings suggest opportunities to preview the clinical outcomes for individual patients and thereby design personalized therapy approaches in future trials.
Authors: Marianne Nordsmark; Søren M Bentzen; Volker Rudat; David Brizel; Eric Lartigau; Peter Stadler; Axel Becker; Markus Adam; Michael Molls; Juergen Dunst; David J Terris; Jens Overgaard Journal: Radiother Oncol Date: 2005-08-10 Impact factor: 6.280
Authors: Christopher H Crane; Lee M Ellis; James L Abbruzzese; Christina Amos; Henry Q Xiong; Linus Ho; Douglas B Evans; Eric P Tamm; Chaan Ng; Peter W T Pisters; Chusilp Charnsangavej; Marc E Delclos; Michael O'Reilly; Jeffrey E Lee; Robert A Wolff Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Mark Muzi; David A Mankoff; John R Grierson; Joanne M Wells; Hubert Vesselle; Kenneth A Krohn Journal: J Nucl Med Date: 2005-02 Impact factor: 10.057
Authors: Carmen Timke; Heike Zieher; Alexandra Roth; Kai Hauser; Kenneth E Lipson; Klaus J Weber; Jürgen Debus; Amir Abdollahi; Peter E Huber Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: Tanguy Y Seiwert; Daniel J Haraf; Ezra E W Cohen; Kerstin Stenson; Mary Ellyn Witt; Allison Dekker; Masha Kocherginsky; Ralph R Weichselbaum; Helen X Chen; Everett E Vokes Journal: J Clin Oncol Date: 2008-04-01 Impact factor: 44.544
Authors: Kaye J Williams; Brian A Telfer; Aoife M Shannon; Muhammad Babur; Ian J Stratford; Stephen R Wedge Journal: Mol Cancer Ther Date: 2007-02 Impact factor: 6.261
Authors: Vishwajith Sridharan; Danielle N Margalit; Stephanie A Lynch; Mariano Severgnini; F Stephen Hodi; Robert I Haddad; Roy B Tishler; Jonathan D Schoenfeld Journal: J Immunother Cancer Date: 2016-06-21 Impact factor: 13.751
Authors: Aini Hyytiäinen; Wafa Wahbi; Otto Väyrynen; Kauko Saarilahti; Peeter Karihtala; Tuula Salo; Ahmed Al-Samadi Journal: Front Oncol Date: 2021-06-14 Impact factor: 6.244